期刊文献+

通瘀煎化裁对瘀血阻络型2型糖尿病患者血清hs-CRP的影响 被引量:3

Effect of Tongyu Cutting Decoction on Blood Stasis Type hs-CRP in Serum of Patients with Type Ⅱ Diabetes
下载PDF
导出
摘要 目的:探究通瘀煎化裁治疗瘀血阻络型2型糖尿病的临床疗效及对患者血清hs-CRP的影响。方法:选择到我院就诊的中医辨证为瘀血阻络型2型糖尿病患者60例,随机分为对照组和观察组各30例。两组均予糖尿病常规治疗,并口服阿司匹林肠溶片,疗程4周,观察组另加服通瘀煎化裁。结果:观察组hs-CRP、中医症候积分改善程度均明显优于对照组,总有效率明显高于对照组。结论:通瘀煎化裁可明显改善患者临床症状,减低瘀血阻络型2型糖尿病患者的hs-CRP值,从而减少体内慢性炎症反应,改善胰岛素抵抗,延缓糖尿病的进展。 Objective:To explore the clinical curative effect and the hs-CRP in Serum of Tongyu Cutting Decoction on blood stasis type in patients with type II diabetes. Methods:60 cases of blood stasis type in patients with type II diabetes were randomly assigned to con-trol group and treatment group with 30 cases in each group according to syndrome differentiation in TCM treatment in our hospital. The two groups were given conventional treatment of diabetes and oral aspirin enteric coated tablets. In the treatment group, the treatment group was treated with Tongyu Cutting Decoction for 4 weeks. Results:The hs-CRP and TCM syndrome score of the treatment group were significantly better than that of the control group, and the total effective rate was significantly higher than that of the control group. Conclusion: Tongyu Cutting Decoction can improve the clinical symptoms of patients obviously and reduce the hs CRP of blood stasis type in patients with type II diabetes to reduce chronic inflammatory response in vivo, improve insulin resistance and delay diabetes progression.
出处 《江西中医药大学学报》 2016年第4期61-63,共3页 Journal of Jiangxi University of Chinese Medicine
关键词 通瘀煎 瘀血阻络 2型糖尿病 HS-CRP hs-CRP Tongyu Decoction Blood Stasis Type Ⅱ Diabetes Hs-CRP
  • 相关文献

参考文献3

  • 1You T, Nicklas BJ, Ding J, et al. The metabolic syndrome is associat- edwith circulating adipokines in older adults across a wide range of ad iposity[J]. Gerontol A Biol Sci Med Sci,2008,63(4) :414 -419.
  • 2鄢盛恺.超敏C反应蛋白测定在动脉粥样硬化疾病诊治中的应用[J].诊断学理论与实践,2002,1(4):267-269. 被引量:109
  • 3Dehghan A, Kardys I, de Maat MP, et al. Genetic Variation, C - reac- tive protein levels, and incidence of diabetes [ J ]. Diabetes, 2007 (56) :872 -878.

二级参考文献20

  • 1[1]Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
  • 2[2]Ledue TB, Rifai N. High sensitivity immunoassays for C-reactive protein: promises and pitfalls[J]. Clin Chem Lab Med, 2001, 39(11):1171-1176.
  • 3[3]Whicher J, Rifai N, Biasucci LM. Markers of the acute phase response in cardiovascular disease: an update[J].Clin Chem Lab Med, 2001, 39(11):1054-1064.
  • 4[4]Rifai N, Ridker PM. High-sensitivity C-reactive protein:a novel and promising marker of coronary heart disease [J]. Clin Chem, 2001,47(3):403-411.
  • 5[5]Morley JJ, Kushner I. Serum C-reactive protein levels in disease[J]. Ann N Y Acad Sci, 1982,389:406-418.
  • 6[8]Rothkrantz-Kos S, Schmitz MP, Bekers O, et al. Highsensitivity C-reactive protein methods examined[J]. Clin Chem, 2002,48(2): 359-362.
  • 7[9]Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina [J]. Circulation, 1999,100 (19):1958-1963.
  • 8[10]Morrow DA, Rifai N, Antman EM, et al. C-Reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy[J]. J Am Coll Cardiol ,1998; 31(7): 1460 -1465.
  • 9[11]de Winter RJ, Bholasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction[J]. Cardiovasc Res, 1999,42 (1):240-245.
  • 10[12]Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [J]. Lancet ,1997, 349(9050): 462-466.

共引文献108

同被引文献28

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部